Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2010-10-03 Capital/Financing Update
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Letter to Shareholders re OMI Holdings Ltd Capital Raising 64 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus dated 24 September 2010 for a capital raising by OMI Holdings Limited, including offers of shares and options, terms of the offer, company background, and legal and financial information related to the capital raising. It includes a timetable for the offer, details of the deed of company arrangement, and information about the company's restructuring and recapitalisation efforts. The document is not a financial report, earnings release, or management discussion but rather a formal offer document for raising capital. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2010-10-03 English
Annual Report 64 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report 30 June 2010' for Sun Biomedical Limited and Controlled Entities. It contains a detailed Table of Contents listing sections typical of an annual report, including Corporate Governance Statement, Report of the Directors, Auditor’s Independence Declaration, full financial statements (Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flow), Notes to the Financial Statements, Declaration by Directors, Independent Auditor’s Report, and Other Information. The content includes detailed corporate governance disclosures, director information, and financial reporting integrity sections, all consistent with a comprehensive annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K).
2010-09-28 English
Preliminary Final Report 13 pages ?Kb
Annual Report Classification · 95% confidence The document is titled 'PRELIMINARY FINAL REPORT APPENDIX 4E FINANCIAL YEAR ENDED 30 JUNE 2010' and contains detailed financial statements including income statement, balance sheet, cash flow statement, and notes. It covers a full fiscal year ending 30 June 2010, with comparative figures for the previous year. The document includes comprehensive financial data, commentary on results, details of share issues and capital raising, and audit status. The presence of full financial statements and detailed analysis indicates this is a full annual financial report rather than a brief announcement or a certification. The Appendix 4E is a regulatory form used in Australia for preliminary final reports, which is equivalent to an annual report or 10-K type filing. Therefore, the document should be classified as an Annual Report (10-K).
2010-08-26 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report is for the quarter ended 30 June 2010, indicating it is a quarterly financial report. The content includes actual financial statements and substantive financial data, not just an announcement or certification. The document length is 7271 characters, which is sufficient for a detailed report. The nature of the report aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains comprehensive financial data and analysis. Therefore, the correct classification is IR (Interim / Quarterly Report).
2010-07-26 English
Update on Convertible Note in SAY 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the redemption payment of convertible notes and related share issuance. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an update on a financing instrument (convertible notes) and related capital structure changes. Given the content and length (852 characters), it fits best under Capital/Financing Update (CAP).
2010-06-30 English
OMI: Deed of Company Arrangement 51 pages ?Kb
Regulatory Filings
2010-06-07 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.